spacer
home > white papers > Pharmacovigilance and Risk Management Information in Centralised Applications in the EU - United BioSource Corporation (UBC)
WHITE PAPERS
logo_United_Bio2.JPG

United BioSource Corporation (UBC)

phone +44 (0) 208.834.0100
email contact@ubc.com
web http://www.ubc.com/europe
email 26-28 Hammersmith Grove London, W6 7HA, United Kingdom

Pharmacovigilance and Risk Management Information in Centralised Applications in the EU

Getting a new medication approved for the EU market through the centralised procedure can be complex and needs expertise. The new EU pharmacovigilance legislation (Good Vigilance Practice, GVP) is now in effect and applicants need to be fully compliant. It is critical to have a thorough understanding of the regulatory process and requirements, and the expectations with regards to the pharmacovigilance system and the risk management plan. Ensuring consistency and an appropriate level of detail in the documentation submitted as part of the approval process will help prevent unnecessary delays.
Pharmacovigilance and Risk Management Information in Centralised Applications in the EU
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Synpromics Announces Gene Therapy Research Partnership with Solid Biosciences

Edinburgh, UK – September 20th, 2017 - Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. Under the terms of the agreement, Synpromics will provide Solid Biosciences access to a set of key muscle-selective promoter candidates to be used in the development of new treatment options for Duchenne muscular dystrophy (DMD).
More info >>


White Papers

pAVEway™ expression system for the efficient expression of therapeutic proteins

Fujifilm Diosynth Biotechnologies

One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells. The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).
More info >>


Industry Events

Global Bioproduction Summit, 5th-6th February 2018

5-6 February 2018, Hilton San Diego Resort & Spa, CA

After 15 years in Europe, the Global Bioproduction Summit moved to its new home of San Diego in 2016. The Bioproduction Summit delves deep into the world of biological production.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement